{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T04:26:36Z","timestamp":1747974396336},"reference-count":42,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T00:00:00Z","timestamp":1287100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2011,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The concept of molecular tumor targeting might be an innovative option to treat advanced prostate cancer. We analyzed the effect of combining the multiple receptor tyrosine kinase inhibitor AEE788 and the histone deacetylase (HDAC) inhibitor valproic acid (VPA) on adhesion and growth properties of prostate cancer cell lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>PC\u20103, DU\u2010145, and LNCaP cells were treated with AEE788, VPA or with an AEE788\u2013VPA combination, and cell cycle progression investigated. Furthermore, tumor cell adhesion to vascular endothelium or to immobilized extracellular matrix proteins was evaluated, and integrin \u03b1 and \u03b2 subtypes were analyzed. Finally, effects of drug treatment on cell signaling pathways were determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>AEE788 moderately and VPA strongly reduced tumor cell adhesion and growth. VPA impaired cell cycle progression and altered the expression level of the cell cycle regulating proteins cdk1, cdk2, cdk4, cyclin B, D1, cyclin E, p21, and p27. VPA also acted on the membranous, cytoplasmic, and gene expression pattern of various integrin \u03b1 and \u03b2 subtypes. AEE788 acted likewise, but more moderately. Combining AEE788 and VPA did not result in an additive anti\u2010tumor effect. Signaling analysis revealed that the EGFr downstream target Akt was similarly modified in the presence of VPA or the VPA\u2013AEE788 combination, but not influenced by AEE788 alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The AEE788\u2013VPA combination has no advantage over VPA monotreatment in vitro. The non\u2010responsiveness of Akt towards AEE788 might be one reason for this phenomenon. Prostate 71:722\u2013735, 2011. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.21288","type":"journal-article","created":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T13:33:46Z","timestamp":1287149626000},"page":"722-735","source":"Crossref","is-referenced-by-count":10,"title":["Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer"],"prefix":"10.1002","volume":"71","author":[{"given":"Steffen","family":"Wedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukasz","family":"Hudak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens\u2010Michael","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Juengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsie","family":"Oppermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20006"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08327.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm554"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp323"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp111"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31818b946b"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000102452"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1161"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3681"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205108"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i33.4458"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn703"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.227"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.20027"},{"key":"e_1_2_7_17_2","first-page":"1417","article-title":"Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells","volume":"35","author":"Cang S","year":"2009","journal-title":"Int J Oncol"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604199"},{"key":"e_1_2_7_19_2","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa M","year":"2007","journal-title":"Oncol Rep"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.05.008"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.104"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.205"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080751"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2222"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.49.34940"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.02.081"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.2.3578"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0019"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1591"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.051649"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001592"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0854.2005.00362.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M701165200"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9388-4"},{"key":"e_1_2_7_35_2","article-title":"Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium","author":"Bradley DA","year":"2010","journal-title":"Invest New Drugs"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2009.01266.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.12.049"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-161"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000217433.48870.37"},{"key":"e_1_2_7_40_2","first-page":"733","article-title":"The dual EGF\/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice","volume":"33","author":"Okamoto K","year":"2008","journal-title":"Int J Oncol"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20995"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08759.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1751"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.21288","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.21288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:54:34Z","timestamp":1700582074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.21288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,15]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,5,15]]}},"alternative-id":["10.1002\/pros.21288"],"URL":"https:\/\/doi.org\/10.1002\/pros.21288","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,15]]}}}